Tier 4 — mechanistic

Quercetin for chronic prostatitis/chronic pelvic pain syndrome

Daniel A Shoskes, J Curtis Nickel
The Urologic clinics of North America 2011 38(3):279

Bibliography

PubMed
PMID 21798389
DOI
10.1016/j.ucl.2011.05.003
Funding
Funding was not confirmed from the indexed record; consult the original publication.
Competing interests
Competing interests were not confirmed from the indexed record; consult the original publication.

Study snapshot

DesignClinical narrative review of chronic prostatitis/chronic pelvic pain syndrome
ModelNarrative or mixed evidence review
SampleNo new trial cohort
InterventionQuercetin as an adjunct within phenotype-directed care
DurationReview article; no new intervention period
EndpointsModel-specific outcomes; see methods and findings

What the study showed, in plain terms

Published in 2011, this source examined prostate and urinary health. Its evidence base was No new trial cohort. It evaluated Quercetin as an adjunct within phenotype-directed care across Review article; no new intervention period.

The review discusses quercetin as one possible component of multimodal chronic pelvic pain care.

Narrative clinical interpretation of a small evidence base, not a new randomized comparison or proof for all urinary diagnoses.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Prostatitis and Chronic Pelvic Pain. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The review discusses quercetin as one possible component of multimodal chronic pelvic pain care.
  • The recorded outcome domains were Model-specific outcomes; see methods and findings.

What this study can and cannot tell us

  • Narrative clinical interpretation of a small evidence base, not a new randomized comparison or proof for all urinary diagnoses.
  • The conclusions inherit the limitations of the underlying studies. A narrative interpretation or guideline recommendation is not a new randomized treatment comparison.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this record. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial
D A Shoskes et al. · Urology · 1999
Tier 2
Treatment of interstitial cystitis with a quercetin supplement
F Katske et al. · Techniques in urology · 2001

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology